LGD-2226 is a new experimental SARM that certain pockets of the internet have begun to talk about.
Like with most new SARMs, LGD-2226 is being developed to help treat muscle and bone wasting diseases such as osteoporosis.
However, this SARM is gaining attention for its purported “clean gains” and slender reported side effects.
Let’s dive straight in.
What is LGD-2226?
LGD-2226 is a new selective androgen receptor modulator or SARM that has shown promise in prelimary studies.
“LGD2226 is a nonsteroidal, nonaromatizable, highly selective ligand for the AR, exhibiting virtually no affinity for the other intracellular receptors. We determined that AR bound to LGD2226 exhibits a unique pattern of protein-protein interactions compared with testosterone, fluoxymesterone (an orally available steroidal androgen), and other steroids, suggesting that LGD2226 alters the conformation of the ligand-binding domain.
“We demonstrated that LGD2226 is fully active in cell-based models of bone and muscle. LGD2226 exhibited anabolic activity on muscle and bone with reduced impact on prostate growth in rodent models. Biomechanical testing of bones from animals treated with LGD2226 showed strong enhancement of bone strength above sham levels. LGD2226 was also efficacious in a sex-behavior model in male rats measuring mounts, intromissions, ejaculations, and copulation efficiency.
“These results with an orally available, nonaromatizable androgen demonstrate the important role of the AR and androgens in mediating a number of beneficial effects in bone, muscle, and sexual function independent from the conversion of androgens into estrogenic ligands. Taken together, these results suggest that orally active, nonsteroidal selective androgen receptor modulators may be useful therapeutics for enhancing muscle, bone, and sexual function.“
Benefits of LGD-2226
Although it has yet to be released for sale, some anecdotal reports have indicated the following benefits:
- muscular gains
- increased bone density
- improved stamina
- increased fat loss
- low side-effect profile
- little suppression
- increased strength and athleticism
- little to no prostate enlargement
At present, it seems that the touted benefits of this new SARM are very similar to other SARMs currently on the market.
The study found: “Tissue-selective agonist activity of LGD2226. A, The muscle weights (levator ani) from eight rats treated for 2 wk with the indicated compound are averaged and plotted as a percentage of sham controls (percent efficacy) together with the SEM. T (F) and LGD2226 (E) were administered in doses up to 100 mg/kg. B, Ventral prostate weights from these same animals are plotted similarly together with the SEM for each dose. C, LH levels in serum are shown relative to sham. In this case, 100% represents sham-like levels of suppression of LH.”
Like with most SARMs, LGD-2226 can be suppressive — and it is advised to run a PCT following a course of SARMs based on your bloodwork.
How to Buy LGD-2226?
As LGD-2226 is still an experimental SARM under investigation, the credibility of products marketed as such should be called into question.
This new SARM is yet to be officially released — and seasoned users should stick to SARMs they are already familiar with.
If you are interested in purchasing SARMs, please visit our trusted provider Swiss Chems.
Don’t hesitate to email us at firstname.lastname@example.org for personalized coaching and a client questionnaire if you’d like DEDICATED tailor-made personal training on strength training, building muscle, losing fat, developing athleticism, and more — all to your liking, lifestyle, habits, and taste!
Alternatively, you can pick up a FREE eBook on fundamental strength principles offering an introductory workout program.